Page 97 - JSOM Spring 2023

a broadly-neutralizing antibody derived from survivors of 9. Whitehouse CA. Crimean–Congo hemorrhagic fever. Antiviral Res.
CCHF that protected mice when administered 24 hours after 2004;64(3):145–160.
a lethal challenge with live virus. 31,32 USAMRIID is currently 10. Leblebicioglu H, Eroglu C, Erciyas-Yavuz K, et al. Role of migratory
birds in spreading Crimean-Congo hemorrhagic fever, Turkey. Emerg
investigating this antibody called DVD-121-801 as a potential Infect Dis. 2014;20(8):1331–1334.
therapeutic for human patients. 31,32 11. Hoogstraal H. Changing patterns of tickborne diseases in modern so-
ciety. Annu Rev Entomol. 1981;26:75–99.
12. Pshenichnaya NY, Sydenko IS, Klinovaya EP, et al. Possible sexual
Conclusion transmission of Crimean-Congo hemorrhagic fever. Int J Infect Dis.
2016;45:109–111.
While rare, CCHF poses an important medical threat to US 13. Ergönül Ö, Keske Ş, Çeldir MG, et al. Systematic review and meta-
SOF operating in endemic regions. CCHF is relatively silent analysis of postexposure prophylaxis for Crimean-Congo Hem-
in nature as most animals do not show signs of infection and orrhagic Fever Virus among healthcare workers. Emerg Infect Dis.
2018;24(9):1642–1648.
initial symptoms are nonspecific in nature. SOF medical pro- 14. Gokhan Gozel M, Dokmetas I, Oztop Y, et al. Recommended pre-
viders must combine a high index of suspicion with a thor- caution procedures protect healthcare workers from Crimean-Congo
ough epidemiologic exposure history when evaluating soldiers hemorrhagic fever virus §. Int J Infect Dis. 2013;17:e1046–e1050.
deployed to endemic regions. Additionally, vigilant insect con- 15. Thomas R, Mathew F, Louis E, et al. Contact tracing for an imported
case of Crimean–Congo Hemorrhagic Fever – experience from a ter-
trol and education remain cornerstones in prevention, while tiary care center in Kerala, South India. Indian J Community Med.
contact precautions, supportive care, and early administration 2019;44(3):285.
of ribavirin are vital components to its management. Special- 16. Nicol ED, Mepham S, Naylor J, et al. Aeromedical transfer of patients
ized aeromedical evacuation platforms if available must also with viral hemorrhagic fever. Emerg Infect Dis. 2019;25(1):5–14.
doi:10.3201/EID2501.180662
be considered given the high transmissibility from patients 17. US Department of Defense. Isolation system the latest in DOD
to healthcare personnel. While no current vaccine exists, sev- medical transport advancement. 1 May 2020. https://www.defense
eral candidates are in development as well as potential anti- .gov/News/Feature-Stories/story/Article/2173482/isolation-system
-the-latest-in-dod-medical-transport-advancement/. Accessed 31 Jan-
body-based therapeutics. SOF medical planners and providers uary 2023.
should consult their combatant command and unit-specific 18. Shayan S, Bokaean M, Shahrivar MR, Chinikar S. Crimean-Congo
doctrine and policies for additional guidance. General infor- Hemorrhagic Fever. Lab Med. 2015;46(3):180–189.
mation and further guidance about viral hemorrhagic fevers is 19. Bente DA, Forrester NL, Watts DM, et al. Crimean-Congo hemor-
rhagic fever: History, epidemiology, pathogenesis, clinical syndrome
available at: https://usamriid.health.mil/education/bluebook- and genetic diversity. Antiviral Res. 2013;100(1):159–189.
pdf/USAMRIID’s%20Blue%20Book%209th%20edition%20 20. Baskerville A, Satti A, Murphy FA, Simpson DI. Congo-Crimean
-%20PDF%20format.pdf haemorrhagic fever in Dubai: histopathological studies. J Clin Path.
1981;34(8):871.
21. Ergonul O, Celikbas A, Baykam N, et al. Analysis of risk-factors among
Disclosure patients with Crimean-Congo haemorrhagic fever virus infection: se-
The authors have no conflicts of interest to disclose. verity criteria revisited. Clin Microbiol Infect. 2006;12(6):551–554.
22. Çevik MA, Erbay A, Bodur H, et al. Clinical and laboratory features
of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J In-
Funding fect Dis. 2008;12(4):374–379.
None. 23. Ergonul O, Tuncbilek S, Baykam N, et al. Evaluation of serum levels
of interleukin (IL)–6, IL-10, and tumor necrosis factor–α in patients
Author Contributions with Crimean-Congo Hemorrhagic Fever. J Infect Dis. 2006;193(7):
941–944.
AS drafted original manuscript. JK and AG contributed addi- 24. Raabe VN. Diagnostic testing for Crimean-Congo Hemorrhagic Fe-
tional sections, figures, and references. All authors reviewed ver. J Clin Microbiol. 2020;58(4).
and approved the final manuscript. 25. World Health Organization. WHO R&D blueprint: priority diagnos-
tics for CCHF: Use scenarios and target product profiles. https://www
.who.int/docs/default-source/blue-print/call-for-comments/who-cchf-
References tpp-dx-draft-v1-0.pdf?sfvrsn=a5b8580_2. Accessed 31 January 2023.
1. Formenty P. Introduction to Crimean-Congo Haemorrhagic Fever. 26. Bakır M, Gözel MG, Köksal, et al. Validation of a severity grading
WHO. 2018. https://cdn.who.int/media/docs/default-source/documents score (SGS) system for predicting the course of disease and mortality
/health-topics/crimean-congo-haemorrhaigc-fever/introduction in patients with Crimean-Congo hemorrhagic fever (CCHF). Eur J
-to-crimean-congo-haemorrhagic-fever.pdf?sfvrsn=14c8c199_2& Clin Microbiol Infect Dis. 2015;34(2):325–330.
download=true. Accessed 31 January 2023. 27. US Army Institute Medical Research Institute of Infectious Diseases.
2. Fillâtre P, Revest M, Tattevin P. Crimean-Congo hemorrhagic fever: An Quick bio-agents: USAMRIID’s pocket reference guide to biological
update. Medecine et Maladies Infectieuses. 2019;49(8):574–585. select agents & toxins. US Department of the Army. 5 April 2012.
3. Stanek S, Saunders D. USAMRIID’s medical management of biolog- 28. US Food & Drug Administration. COPEGUS (Ribavirin): FDA
ical casualties handbook. 9th Ed. 2021. https://usamriid.health.mil/ medication guide. https://www.accessdata.fda.gov/drugsatfda_docs/
education/bluebookpdf/USAMRIID’s%20Blue%20Book%209th%20 label/2011/021511s023lbl.pdf. Accessed 31 January 2023.
edition%20-%20PDF%20format.pdf. Accessed 31 January 2023. 29. Tipih T & Burt FJ. Crimean-Congo Hemorrhagic Fever Virus: Advances
4. Conger NG, Paolino KM, Osborn EC, et al. Health care response to in vaccine development. BioRes Open Access. 2020;9(1):137–150.
CCHF in US soldier and nosocomial transmission to health care provid- 30. Suschak JJ, Golden JW, Fitzpatrick CJ, et al. A CCHFV DNA vaccine
ers, Germany, 2009. Emerg Infect Dis. 2015;21(1):23–31. doi:10.3201/ protects against heterologous challenge and establishes GP38 as im-
EID2101.141413 munorelevant in mice. NPJ Vaccines. 2021;6(1):1–11.
5. Centers for Disease Control. Bioterrorism agents/diseases (by category). 31. Fels JM, Maurer DP, Herbert AS, et al. Protective neutralizing anti-
https://emergency.cdc.gov/agent/agentlist-category.asp. Accessed 31 Jan- bodies from human survivors of Crimean-Congo hemorrhagic fever.
uary 2023. Cell. 2021;184(13):3486-3501.e21.
6. Hoogstraa H. The epidemiology of tick-borne Crimean-Congo Hemor- 32. Vanderlinden T. Scientists develop novel therapy for Crimean-Congo
rhagic Fever in Asia, Europe and Africa. J Med Entomol 1979;15(4): Hemorrhagic Fever Virus. USAMRIID Press Release. 1 June 2021.
307–417. https://www.usamriid.army.mil/press_releases/Final%20release%20
7. Kuehnert PA, Stefan CP, Badger C v, Ricks KM. Crimean-Congo Hem- Cell%20paper%20CCHF%20June%202021.pdf. Accessed 31 Janu-
orrhagic Fever Virus (CCHFV): A silent but widespread threat. Curr ary 2023.
Trop Med Rep. 2021;8(2):1–7. 33. Centers for Disease Control. Outbreak distribution map | Crimean-
8. World Health Organization. Geographic distribution of Crimean- Congo Hemorrhagic Fever (CCHF). https://www.cdc.gov/vhf/crimean
Congo Haemorrhagic Fever. https://www.who.int/health-topics/crimean -congo/outbreaks/distribution-map.html. Accessed 31 January 2023.
-congo-haemorrhagic-fever/#tab=tab_1. Accessed 31 January 2023.

Crimean-Congo Hemorrhagic Fever | 95